Board of Directors
Damian Lamb – Director – Mr. Lamb is co-Founder and Managing Director of Genesys Capital, a Canadian-based venture capital firm exclusively focused on the life sciences industry. Mr. Lamb brings a unique experience base, blending skills in both the commercial and technical side of biotechnology. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $225 million in venture capital funds and has been involved in deploying over $140 million across 28 investments. Other than Profound, Mr. Lamb currently serves on the board of directors of Affinium Pharmaceuticals Inc. and the Centre for Probe Development and Commercialization at McMaster University. Mr. Lamb has served on the board of directors of Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the board of directors of DELEX Therapeutics Inc. when it was sold to YM BioSciences. Mr. Lamb works closely with Genesys Capital investee companies to strategically position the companies to build value for shareholders. Prior to co-founding Genesys Capital, Mr. Lamb was an investment manager with MDS Capital Corp. Mr. Lamb is a frequently invited speaker at biotechnology industry conferences. Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with an M.S. in Molecular Neurobiology and also holds a Master of Business Administration from Queen’s University.
Jean-François Pariseau – Director – Mr. Pariseau is Partner in the BDC Capital Healthcare Fund. Mr. Pariseau joined BDC Venture Capital in 2001 and has over 20 years of investment and entrepreneurial experience in the healthcare sector. Prior to joining BDC Capital Healthcare Fund, Mr. Pariseau was an investment manager with CDP Capital Technology Ventures, a $2 billion global fund investing in healthcare, information technology and advanced technologies, where Mr. Pariseau was responsible for healthcare investments in Canada and the United States. Mr. Pariseau has invested and managed more than $200 million in biopharmaceutical and medical device companies in North America. His experience includes transactions in private and in public companies, IPOs, M&A and fund investments. Prior to this, Mr. Pariseau was CEO of a consulting company specializing in regulatory affairs, and was VP, R&D for a pharmaceutical-product distribution company, both of which he founded. Mr. Pariseau also sits on the board of directors of AngioChem, Clementia Pharmaceutical, Imagia Cybernetics, MedDev Commercialization Centre for medical devices and is an advisor to Hacking Health. Mr. Pariseau holds a Bachelor of Science in Biotechnology from Université de Sherbrooke, a Master of Science in Biomedical Sciences from Université de Montréal, and an MBA from HEC Montréal.
Arun Menawat – Director – Dr. Menawat joined Profound as Chief Executive Officer in August 2016 and has been a member of the Board for approximately two years prior to joining the Corporation. Previously. Dr. Menawat was the President and Chief Executive Officer of Novadaq Technologies Inc., for 13 years, guiding the company from a start-up to a fast growing, NASDAQ listed medical imaging company in North America, with a market cap of approximately $1 billion at the time of his departure. Previously, Dr. Menawat was President of Cedara, a medical imaging software company and held senior positions at Tenneco Inc. and Hercules Inc. Dr. Menawat currently serves on the board of directors of Stereotaxis and EIMindA and as an advisor to Baylis Medical. Dr. Menawat’s educational background includes a Ph.D. in Chemical Engineering, from the University of Maryland, College Park, MD, and an Executive MBA from the J.L. Kellogg School of Management, Northwestern University, Evanston, Illinois.
Brian Ellacott – Director – Mr. Ellacott is an experienced global medical device executive. Mr. Ellacott joined Belmont Instrument as Chief Executive Officer in December 2017. Belmont is a Boston based private equity owned medical device company with a leading global position in fluid warming and infusion systems. Prior to Belmont, Mr. Ellacott was the President and CEO of Laborie Medical Technologies (“Laborie”). Laborie is a Urology and Gastroenterology medical device company based in Toronto with manufacturing facilities in Toronto, Montreal, Enschede NL, Attikon Switzerland and Portsmouth New Hampshire. Mr. Ellacott joined private equity owned Laborie as President and CEO in July 2013 and in four years completed 14 global acquisitions tripling Laborie’s revenue and increasing EBITDA eight fold. The company was ranked as one of the fastest growing and most profitable medical device companies in the world. Prior to joining Laborie, Mr. Ellacott served as Executive Vice President and General Manager of Invacare’s (NYSE:IVC) $1 billion North and South American homecare and rehabilitation business. Mr. Ellacott has also held executive positions with Baxter International and American Hospital Supply, with assignments in Canada, Australia and the United States. Mr. Ellacott serves on the board of Belmont and is the past Chairman of the board of the Canadian Assistive Devices Association. Mr. Ellacott holds a Bachelor of Business Administration Degree from Laurier University, Waterloo, Ontario Canada and is a dual United States and Canadian citizen.
Clinical Advisory Board
Profound Medical’s research and clinical trials are further informed by the considerable collective expertise of well-experienced clinicians, specializing in urology and radiology.
Peter Albertsen, Chief and Program Director of the Division of Urology, Professor of Surgery, University of Connecticut Health Center
Scott Eggener, Co-Director, Prostate Cancer Program Director, Translational and Outcomes Research, Section of Urology, Associate Professor of Surgery, University of Chicago
Adam Kibel, Chief of Urology, Brigham and Women’s Hospital Chief of Urology, Dana-Farber Cancer Institute, Professor of Surgery, Harvard Medical School, Dana-Farber/Harvard Cancer Center
Eric Klein, Chairman of the Glickman Urological and Kidney Institute, Professor of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland Clinic